Opthea (ASX:OPT) has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.
The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.
The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.
The company sees unaudited cash and cash equivalents of $100 million at the end of March.
The company said its ability to continue as a going concern remains materially uncertain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.